ROS1 and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKIs) targeting ROS1 fusions (ROS1+) are currently approved and recommended as the preferred first-line options in clinical guidelines for treating ROS1+ locally advanced or metastatic non-small-cell lung cancer (aNSCLC) [6,7,8,9,10,11,12].